The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Mergers & AcquisitionsMedium•1 May 2026•

1 min read

Siegfried Holding Completes Acquisition of Noramco Group to Bolster CDMO Leadership

Key Facts

1Siegfried Holding AG completed the acquisition of Noramco, Extractas Biosciences, and Purisys from SK Capital Partners.

2Siegfried is a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry.

Siegfried Holding AG has officially finalized the acquisition of the Noramco Group, including its subsidiaries Extractas Biosciences and Purisys, from SK Capital Partners. This strategic move solidifies Siegfried's position as a premier global Contract Development and Manufacturing Organization (CDMO) within the pharmaceutical industry. By integrating Noramco’s specialized capabilities, Siegfried aims to enhance its service offerings and broaden its international market reach. The acquisition is expected to drive operational synergies and foster innovation in advanced pharmaceutical solutions. This transaction underscores Siegfried’s ongoing growth strategy and its commitment to scaling production capacity. The completion of this deal marks a significant milestone in the company's expansion within the life sciences sector.